Evidence map›Paper›PMID 32160286›Full record

ArticleHuman molecular genetics2020

Knockin mouse model of the human CFL2 p.A35T mutation results in a unique splicing defect and severe myopathy phenotype.

Samantha M Rosen, Mugdha Joshi, Talia Hitt, Alan H Beggs, Pankaj B Agrawal

Open access · greenAbstract read
In one paragraph

Article in Human molecular genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Samantha M RosenDivision of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mugdha JoshiDivision of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Talia HittDivision of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Alan H BeggsDivision of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Pankaj B AgrawalDivision of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Boston Children's Hospital · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USHarvard University · US

Funding

Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
SPEG is Critical in Skeletal Muscle Development and FunctionR01AR068429 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI AGRAWAL, PANKAJ B · 2015 to 2019
$1.9M
Genetic screening and therapies for nemaline myopathiesR01HD075802 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI BEGGS, ALAN H. · 2014 to 2018
$1.8M
NIAMS NIH HHS R01 AR068429NICHD NIH HHS R01 HD075802NICHD NIH HHS U54 HD090255
6 · The paper itself

Abstract

Cofilin-2 is an actin-binding protein that is predominantly expressed in skeletal and cardiac muscles and belongs to the AC group of proteins, which includes cofilin-1 and destrin. In humans, cofilin-2 (CFL2) mutations have been associated with congenital myopathies that include nemaline and myofibrillar myopathy. To understand the pathogenicity of the human CFL2 mutation, p.A35T, that first linked cofilin-2 with the human disease, we created a knock-in mouse model. The Cfl2A35T/A35T (KI) mice were indistinguishable from their wild-type littermates at birth, but they rapidly worsened and died by postnatal day 9. The phenotypic, histopathologic and molecular findings mimicked the constitutive Cfl2-knockout (KO) mice described previously, including sarcomeric disruption and actin accumulations in skeletal muscles and negligible amounts of cofilin-2 protein. In addition, KI mice demonstrated a marked reduction in Cfl2 mRNA levels in various tissues including skeletal muscles. Further investigation revealed evidence of alternative splicing with the presence of two alternate transcripts of smaller size. These alternate transcripts were expressed at very low levels in the wild-type mice and were significantly upregulated in the mutant mice, indicating that pre-translational splicing defects may be a critical component of the disease mechanism associated with the mutation. Evidence of reduced expression of the full-length CFL2 transcript was also observed in the muscle biopsy sample of the patient with p.A35T mutation.

Indexed as

Genetic Predisposition to DiseaseActinsAnimalsCofilin 2Disease Models, AnimalGene Knock-In TechniquesHumansMiceMice, KnockoutMicrofilament ProteinsMuscle, SkeletalMuscular DiseasesMutationPhenotypeRNA, MessengerActinsCFL2 protein, humanCfl2 protein, mouseCofilin 2Microfilament ProteinsRNA, Messenger

Identifiers

PMID32160286
PMCPMC7390935
OpenAlexW3012001127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.